Skip to main content
SpringerLink
Log in

The Ideal Drug for Treatment of Osteoporosis

  • Chapter
Clinical Trials in Osteoporosis

Part of the book series: Clinical Trials ((CLINICAL))

  • 740 Accesses

Abstract

The ideal drug for treatment of osteoporosis is one that replaces lost bone and restores its disorganized microarchitecture so that fracture risk is reduced to that of the normal population. The drug should be free of side effects and sufficiently inexpensive for widespread use. Its beneficial effects on bone should persist for a significant time once therapy is withdrawn, opening the way to intermittent courses of treatment. It should be effective when given by a variety of routes, to improve subject acceptance and maintain compliance. Such a drug is not available, but several of the currently available compounds fulfil some (but not all) of the requirements and point the way to the future optimization of therapy. There have also been several important recent advances in our understanding of the cell biology of bone, which could also lead to the development of better treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. (1993). Consensus Development Conference: diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 94:646–50.

    Google Scholar 

  2. Riggs, B.L., Hodgson, S.F., O’Fallon, W.M. et al. (1990). Effect of fluoride treatment on fracture rate in postmenopausal women with osteoporosis. N Engl J Med 22:802–9.

    Article  Google Scholar 

  3. Eiken, P., Kolthoff, N. and Pors Nielsen, S. (1996). Effects of 10 years’ hormone replacement therapy on bone mineral content in postmenopausal women. Bone 19:1915–35.

    Article  Google Scholar 

  4. Storm, T., Killerup, G., Thamsborg, G. et al. (1996). Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis. J Rheumatol 23:1560–4.

    PubMed  CAS  Google Scholar 

  5. Devogelaer, J.P., Broll, H., Correa-Potter, R. et al. (1996). Oral alendronate induced progressive increases in bone mass of the spine, hip and total body over 3 years in postmenopausal women with osteoporosis. Bone 18:141–50.

    Article  PubMed  CAS  Google Scholar 

  6. Lindsay, R., Nieves, J., Formica, C. et al. (1997). Randomised controlled study of effect of parathyroid hormone on vertebral bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550–5.

    Article  PubMed  CAS  Google Scholar 

  7. Mosekilde, L., Eriksen, E.F. and Charles, P. (1991). Hypercalcaemia of malignancy: pathophysiology, diagnosis and treatment. Crit Rev Oncol Haematol 11:1–27.

    CAS  Google Scholar 

  8. Meunier, P.J. and Bolvin, G. (1997). Bone mineral density reflects bone mass but also the degree of mineralisation of bone: therapeutic implications. Bone 21:373–7.

    Article  PubMed  CAS  Google Scholar 

  9. Chestnut, C.H., McClung, M.R., Ensrud, K.E. et al. (1995). Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodelling. Am J Med 99:44–152.

    Google Scholar 

  10. Garnero, P., Shih, W.J., Gineyts, E. et al. (1994). Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693–700.

    Article  PubMed  CAS  Google Scholar 

  11. Fleisch, H. (1993). New bisphosphonates in osteoporosis. Osteoporos Int Suppl 2:S15–22.

    Article  Google Scholar 

  12. Ravn, P., Bidstrup, M., Wasnich, R.D. et al. (1999). Alendronate and estrogen-progestin prevent bone loss in healthy postmenopausal women: 4 year results from the Early Postmenopausal Intervention Cohort (EPIC) study, a randomised clinical trial. Ann Intern Med 11:935–42.

    Google Scholar 

  13. Christiansen, C., Christensen, M.S. and Transbol, I. (1981). Bone mass after withdrawal of oestrogen replacement. Lancet 1:1053–4.

    Article  PubMed  CAS  Google Scholar 

  14. Delmas, P.D., Bjarnason, N.H., Mitlak, B.H. et al. (1997). Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641–7.

    Article  PubMed  CAS  Google Scholar 

  15. Liberman, U.A., Weiss, S.R., Broll, J. et al. (1995). Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437–43.

    Article  PubMed  CAS  Google Scholar 

  16. Chestnut, C.H., 3rd, Silverman, S., Andriano, K., et al. (2000). A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF study group. Am J Med 109:267–76.

    Article  Google Scholar 

  17. Khairi, M.R.A., Altman, R.D., DeRosa, G.P. et al. (1977). Sodium etidronate in the treatment of Paget’s disease of bone. Ann Intern Med 87:656–63.

    PubMed  CAS  Google Scholar 

  18. Balena, R., Toolan, B.C., Shea, M. et al. (1993). The effect of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry and bone strength in ovariectomised non human primates. J Clin Invest 92:2577–86.

    PubMed  CAS  Google Scholar 

  19. Reid, I.R., Nicholson, G.C., Weinstein, R.S. et al. (1996). Biochemical and radiologic improvement in Paget’s disease of bone treated with alendronate: A randomized, placebo-controlled trial. Am J Med 171:341–8.

    Article  Google Scholar 

  20. Storm, T., Thamsborg, G., Steiniche, T. et al. (1990). Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265–71.

    Article  PubMed  CAS  Google Scholar 

  21. Harris, S.T., Watts, N.B., Genant, H.K. et al. (1999). Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis. JAMA 282:1344–52.

    Article  PubMed  CAS  Google Scholar 

  22. Marshall, D., Johnell, O. and Wedel, H. (1996). Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254–9.

    PubMed  CAS  Google Scholar 

  23. Barrett-Connor, E. (1995). The economic and human cost of osteoporotic fracture. Am J Med 98(Suppl 2A):3S–8S.

    Article  PubMed  CAS  Google Scholar 

  24. Ettinger, B., Black, D.M., Mitlak, B. et al. (1999). Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA 282:637–45.

    Article  PubMed  CAS  Google Scholar 

  25. Ringe, J.D., Kippshoven, C., Coster, A. et al. (1999). Therapy of established postmenopausal osteoporosis with monofluorophosphate plus calcium: dose-related effects on bone density and fracture rate. Osteoporos Int 9:171–8.

    Article  PubMed  CAS  Google Scholar 

  26. Adami, S., Braga, V., Squaranti, R. et al. (1998). Bone measurements in asymptomatic primary hyperparathyroidism. Bone 22:565–70.

    Article  PubMed  CAS  Google Scholar 

  27. Black, D.M., Cummings, S.R., Karpf, D.B. et al. (1996). Randomised trial of effects of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535–41.

    Article  PubMed  CAS  Google Scholar 

  28. Reid, I.R., Ames, R.W., Evans, M.C. et al. (1995). Long-term effects of calcium supplementation on bone loss and fractures in post-menopausal women: a randomized controlled trial. Am J Med 98:331–5.

    Article  PubMed  CAS  Google Scholar 

  29. Dawson-Hughes, B., Harris, S.S., Krall, E.A. et al. (1997). Effect of calcium and Vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337:670–6.

    Article  PubMed  CAS  Google Scholar 

  30. Tilyard, M.W., Spears, G.F.S., Thomson, J. (1992). Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326:357–62.

    Article  PubMed  CAS  Google Scholar 

  31. De Groen, P.C., Lubbe, D.F., Hirsch, L.J. et al. (1996). Esophagitis associated with the use of alendronate. N Engl J Med 335:1016–21.

    Article  PubMed  Google Scholar 

  32. Kumbar, V., Green, S., Stack, G. et al. (1987). Functional domains of the human estrogen receptor. Cell 51:941–51.

    Article  Google Scholar 

  33. Colditz, G.A., Hankinson, S.E., Hunter, D.J. et al. (1995). The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332:1589–93.

    Article  PubMed  CAS  Google Scholar 

  34. Sambrook, P., Birmingham, J., Kelly, P. et al. (1993). Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 328:1747–52.

    Article  PubMed  CAS  Google Scholar 

  35. Tan, A.U., Levine, B.S., Mazess, R.B. et al. (1997). Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in haemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 51:317–23.

    Article  PubMed  CAS  Google Scholar 

  36. Aaron, J.E., Francis, R.M., Peacock, M. et al. (1989). Contrasting micro-anatomy of idiopathic and corticosteroid induced osteoporosis. Clin Orthop 243:294–305.

    PubMed  Google Scholar 

  37. Adachi, J.D., Bensen, W.G., Brown, J. et al. (1997). Intermittent etidronate therapy to prevent corticosteroid induced osteoporosis. N Engl J Med 337:382–7.

    Article  PubMed  CAS  Google Scholar 

  38. Saag, K., Emkey, R., Schnitzer, T.J. et al. (1998). Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339:292–9.

    Article  PubMed  CAS  Google Scholar 

  39. Herd, R.J.M., Balena, R., Blake, G.M. et al. (1997). The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double blind, placebo controlled study. Am J Med 103:92–9.

    Article  PubMed  CAS  Google Scholar 

  40. Anderson, F.H., Francis, R.M., Bishop, D.J. et al. (1997). Effect of intermittent cyclical disodium etidronate on bone mineral density in men with vertebral fractures. Age Ageing 156:359–65.

    Article  Google Scholar 

  41. Jilka, R.L. (1998). Cytokines, bone remodeling and estrogen deficiency: a 1998 update. Bone 23:75–81.

    Article  PubMed  CAS  Google Scholar 

  42. Jilka, R.L., Weinstein, R.S., Bellido, T. et al. (1999). Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104:439–46.

    Article  PubMed  CAS  Google Scholar 

  43. Harris, S.T., Watts, N.B., Jackson, R.D. et al. (1993). Four year study of intermittent cyclical Etidronate treatment of post-menopausal osteoporosis; three years of blinded therapy followed by one year of open therapy. Am J Med 95:557–67.

    Article  PubMed  CAS  Google Scholar 

  44. Hosking, D.J., Chilvers, C.E.D., Christiansen, C. et al. (1998). Prevention of bone loss with Alendronate in postmenopausal women under 60 years of age. N Engl J Med 338:485–92.

    Article  PubMed  CAS  Google Scholar 

  45. Seeman, E. and Delmas, P.D. (2001). Reconstructing the skeleton with intermittent parathyroid hormone. Trends Endocrinol Metab 12:281–3.

    Article  PubMed  CAS  Google Scholar 

  46. Dempster, D.W., Cosman, F., Kurland, E.S. et al. (2001). Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis a paired biopsy study. J Bone Miner Res 16:1846–53.

    Article  PubMed  CAS  Google Scholar 

  47. Zhou, H., Shen, V., Dempster, D.W. et al. (2001). Continuous parathyroid hormone and estrogen administration increases vertebral cancellous bone volume and cortical width in the estrogen-deficient rat. J Bone Miner Res 16:1300–7.

    Article  PubMed  CAS  Google Scholar 

  48. Neer, R.M., Arnaud, C.D., Zanchetta, J.R. et al. (2001). Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–41.

    Article  PubMed  CAS  Google Scholar 

  49. Cosman, F., Nieves, J., Woelfert, L. et al. (2001). Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 16:925–31.

    Article  PubMed  CAS  Google Scholar 

  50. Rittmaster, R.S., Bolognese, M., Ettinger, M.P. et al. (2000). Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85:2129–34.

    Article  PubMed  CAS  Google Scholar 

  51. Samnegård, E., Akhter, M.P. and Recker, R.R. (2001). Maintenance of vertebral body bone mass and strength created by human parathyroid hormone treatment in ovariectomized rats. Bone 28:414–22.

    Article  PubMed  Google Scholar 

  52. Samnegård, E., Iwaniec, U.T., Cullen, D.M. et al. (2001). Maintenance of cortical bone in human parathyroid hormone(1–84)-treated ovariectomized rats. Bone 28:251–60.

    Article  PubMed  Google Scholar 

  53. Iwaniec, U.T., Samnegård, E., Cullen, D.M. et al. (2001). Maintenance of cancellous bone in ovariectomized, human parathyroid hormone [hPTH (1–84)]-treated rats by estrogen, risedronate, or reduced hPTH, Bone 29:352–60.

    Article  PubMed  CAS  Google Scholar 

  54. Meunier, P.J., Roux, C., Seeman, E. et al. (2004). The effect of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–68.

    Article  PubMed  CAS  Google Scholar 

  55. Tonino, R.P., Meunier, P.J., Emkey, R. et al. (2000). Skeletal benefits of alendronate; 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 85:3109–15.

    Article  PubMed  CAS  Google Scholar 

  56. Bone, H.G., Hosking, D., Devogelaer, J-P. et al. (2004). Ten years experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189–99.

    Article  PubMed  CAS  Google Scholar 

  57. McClung, M.R., Wasnich, R.D., Hosking, D.J. et al. (2004). Prevention of postmenopausal bone loss: six year results from the Early Postmenopausal Intervention Cohort study. J Clin Endocrinol Metab 89:4879–85.

    Article  PubMed  CAS  Google Scholar 

  58. Wasnich, R.D., Bagger, Y.Z., Hosking, D.J. et al. (2005). Changes in bone density and turnover after alendronate or estrogen withdrawal. Menopause 11:622–30.

    Article  Google Scholar 

  59. Black, D.M., Bilezikian, J.P., Ensrud, K.E. et al. (2005). One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med 353:555–65.

    Article  PubMed  CAS  Google Scholar 

  60. Wasnich, R.D. and Miller, P.D. (2000). Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85:231–6.

    Article  PubMed  CAS  Google Scholar 

  61. Hochberg, M.C., Greenspan, S., Wasnich, R.D. et al. (2002). Changes in bone density and turnover explain the reductions in incidence of non-vertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:1586–92.

    Article  PubMed  CAS  Google Scholar 

  62. Parfitt, A.M. (2002). Misconceptions (2): turnover is always higher in cancellous than cortical bone. Bone 30:807–9.

    Article  PubMed  CAS  Google Scholar 

  63. Cranney, A., Guyatt, G., Griffin, L. et al. (2002). Summary of meta-analysis of therapies for postmenopausal osteoporosis. (2002). Endocr Rev 23:570–8.

    Article  PubMed  CAS  Google Scholar 

  64. Schnitzer, T., Bone, H.G., Crepaldi, G. et al. (2000). Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin Exp Res 12:1–12.

    CAS  Google Scholar 

  65. Brown, J.P., Kendler, D.L., McClung, M.R. et al. (2002). The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 71:103–11.

    Article  PubMed  CAS  Google Scholar 

  66. Cramer, J.A., Amonkar, M.M., Hebborn, A. et al. (2005). Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21:1453–60.

    Article  PubMed  CAS  Google Scholar 

  67. Delmas, P.D., Recker, R.R., Chestnut, C.H., 3rd, et al. (2004). Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 15:792–8.

    Article  PubMed  CAS  Google Scholar 

  68. Chestnut, C.H., 3rd, Skag, A., Christiansen, C. et al. (2004). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241–9.

    Article  CAS  Google Scholar 

  69. Miller, P.D., McClung, M.R., Macovei, L. et al. (2005). Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE Study. J Bone Miner Res 20:1315–22.

    Article  PubMed  CAS  Google Scholar 

  70. Adami, S., Felsenberg, D., Christiansen, C. et al. (2004). Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 34:881–9.

    Article  PubMed  CAS  Google Scholar 

  71. Reid, I.R., Brown, J.P., Burckhardt, P. et al. (2002). Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653–61.

    Article  PubMed  CAS  Google Scholar 

  72. Thompson, K. and Rogers, M.J. (2004). Statins prevent bisphosphonate-induced γ,δ-T-cell proliferation and activation in vivo. J Bone Miner Res 19:278–88.

    Article  PubMed  CAS  Google Scholar 

  73. Bekker, P.J., Holloway, D.L., Rasmussen, A.S. et al. (2004). A single-dose placebocontrolled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19:1059–66.

    Article  PubMed  CAS  Google Scholar 

  74. Writing Group for the Women’s Health Initiative Investigators (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288:321–33.

    Article  Google Scholar 

  75. Beral, V.; for the Million Women Study Collaborators (2003). Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419–27.

    Article  PubMed  CAS  Google Scholar 

  76. Black, D.M., Greenspan, S.L., Ensrud, K.E. et al. (2003). The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207–15.

    Article  PubMed  CAS  Google Scholar 

  77. Orwoll, E., Ettingham, M., Vice, S. et al. (2000). Alendronate for the treatment of osteoporosis in men. N Eng J Med 343:604–10.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nottingham University Hospitals NHS Trust, Nottingham, UK

    Professor David J. Hosking

Authors
  1. Professor David J. Hosking
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medical Physics & Clinical Engineering Department, Nottingham University Hospitals NHS Trust, Nottingham, UK

    Derek Pearson BSc, PhD (Joint Service Manager) (Joint Service Manager)

  2. Medical Affairs, Bio-Imaging Technologies Inc., Newtown, PA, USA

    Colin G. Miller PhD, FICR (Sr. Vice President) (Sr. Vice President)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag London Limited

About this chapter

Cite this chapter

Hosking, D.J. (2007). The Ideal Drug for Treatment of Osteoporosis. In: Pearson, D., Miller, C.G. (eds) Clinical Trials in Osteoporosis. Clinical Trials. Springer, London. https://doi.org/10.1007/978-1-84628-587-5_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-84628-587-5_11

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84628-389-5

  • Online ISBN: 978-1-84628-587-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation